Building better therapy for children with acute lymphoblastic leukemia.
Childhood acute lymphoblastic leukemia is one of the most curable of all human cancers, but new approaches are urgently needed for children who relapse and to avoid severe side effects of curative therapy. Work from the laboratories of Rob Pieters and William Evans, including a paper in this issue of Cancer Cell, has led to the identification of genes whose expression correlates with drug crossresistance and long term outcome. The goal is now to integrate these and other findings using gene expression technology into the care of children with the most common pediatric malignancy.
Carroll
William L
WL
Stephen D. Hassenfeld Children's Center for Cancer and Blood Diseases, New York University Cancer Institute, New York, New York 10016, USA. william.carroll@nyumc.org
Raetz
Elizabeth A
EA
D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001215:Asparaginase / Q000494:pharmacology; D002648:Child; D018432:Drug Resistance, Multiple / Q000235:genetics; D019008:Drug Resistance, Neoplasm / Q000235:genetics; D020869:Gene Expression Profiling; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D006801:Humans; D009364:Neoplasm Recurrence, Local; D010641:Phenotype; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy* / Q000235:genetics; D016896:Treatment Outcome; D014750:Vincristine / Q000494:pharmacology
D000970:Antineoplastic Agents; D014750:Vincristine; D001215:Asparaginase